| Name | Title | Contact Details |
|---|
Bayer MaterialScience is the global market leader in polyurethanes. The company develops and produces the components for rigid and flexible foams as well as for solid materials. Diverse applications range from mattresses and ski boots to insulating materials for refrigeration appliances and buildings. Bayer MaterialScience is also the leader in the development and production of polycarbonates. Lightweight, tough and freely formable, these high-performance plastics can be used in a wide variety of applications, including in the automotive and construction industries. Bayer MaterialScience is also one of the world’s leading suppliers of raw materials for coatings, adhesives and sealants. These products protect and enhance the appearance of such things as automobiles and furniture, and are used in the sports and leisure sector. In addition, Bayer MaterialScience supplies the chemical industry with numerous basic chemicals.
The Mason City Clinic was formed on January 1, 1989, with the merger of three physician groups -- Surgical Associates, Internal Medicine Associates and Independent Medical Surgical Group.
Executive Source International is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cenduit is the leading IRT systems specialist in the world, with rapid study startup software, clinical supply chain intelligence, clinical operations know-how and customer-centric CORE teams making sure your study starts quickly and runs smoothly. Other IRT-driven services include patient randomization and trial supply management (RTSM), integration, patient engagement and materials forecasting. We have over 500 experts worldwide in the US, UK, Switzerland, India, Japan and China, with clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. Let Cenduit`s experts ensure that your study needs are met on time and within budget.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.